icon-    folder.gif   Conference Reports for NATAP  
  22nd Conference on Retroviruses and
Opportunistic Infections
Seattle Washington Feb 23 - 26, 2015
Back grey_arrow_rt.gif
Marijuana Use Does Not Accelerate Liver Fibrosis in HCV/HIV-Coinfected Women
  Reported by Jules Levin
CROI 2015, Feb 23-26, Seattle, WA
Erin Kelly1, Jennifer Dodge1, Monika Sarkar1, Phyllis Tien1, Marion Peters1, Audrey French2, Marshall Glesby3, Elizabeth Golub4, Michael Augenbraun5, Michael Plankey6 1 Medicine, University of California San Francisco, San Francisco, California, United States;2 CORE Center/Stroger Hospital, Chicago, Illinois, United States;3 Weill Cornell Medical College, New York City, New York, United States;4 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States;5 State University of New York, Downstate Medical Center, Brooklyn, New York, United States;6 Georgetown University, Washington, District of Columbia, United States
from Jules: a number of years ago a bunch of studies were conducted finding marijuana was associated with progression of liver disease, I presume that was 1 reason why this study the subject of this poster was conducted, here are links to some of those earlier studies:
Daily Cannabis Use by HCV+ Increased Odds of Moderate to Severe Fibrosis by 7- Fold.....http://www.natap.org/2006/AASLD/AASLD_07.htm
Influence of Cannabis Use on Severity of Hepatitis C Disease.....http://www.natap.org/2008/HCV/012908_01.htm ......"....In summary, we found that daily cannabis use was significantly associated with the presence of moderate to severe fibrosis compared with mild fibrosis in persons with chronic HCV infection. Furthermore, daily cannabis use and moderate to heavy alcohol use appeared to have at least multiplicative effects on the odds of severe fibrosis. On the basis of our results, we would advise that individuals with chronic HCV infection be counseled to reduce or abstain from cannabis use....daily cannabis users having nearly 7-fold higher odds of moderate to severe fibrosis compared with non-daily users. HCV-HIV coinfected subjects were significantly more likely to use cannabis daily and to have a prescription for medical cannabis than HCV monoinfected subjects. The recommendation to avoid cannabis use might be especially important for HCV-HIV coinfected persons, given that fibrosis progression is already enhanced in this group
Daily Cannabis Smoking as a Risk Factor for Fibrosis Progression in Chronic Hepatitis C.....http://www.natap.org/2005/HCV/062705_01.htm
(Marijuana/Hash) Endocannabinoids and liver disease - review.....http://www.natap.org/2005/HCV/091905_01.htm


program abstract-
Background: Cannabis (THC) use has been correlated with liver fibrosis progression in retrospective analyses of mono-infected chronic hepatitis C (HCV) patients, particularly in those with established fibrosis. We studied long-term effects of THC on fibrosis progression in women co-infected with HCV/HIV enrolled in Women's Interagency HIV Study (WIHS), a prospective, multicenter, cohort of women with or at risk for HIV infection.
Methods: Liver fibrosis was categorized according to APRI scores as mild ( Results: Among 670 HIV/HCV co-infected women (median follow-up: 5.1 (1.2-10.5) years), 323 (49%) reported no THC use; 209 (31%) reported ≥weekly use; 134 (20%)< weekly use; and 4 no THC data. Median APRI at entry were similar (0.53 vs 0.49 vs 0.50) in those who reported no THC use,< weekly use and ≥ weekly use, respectively. Compared to women reporting no THC use, weekly users reported more injection drug [28% vs 18% p=0.004] and alcohol use [60% vs 44% p=0.001]. In univariate analysis, log APRI [HR 10.35 (5.69-18.84) p
Conclusions: In this large cohort of HCV/HIV co-infected women with prospectively collected cumulative alcohol and THC use, THC was not associated with liver fibrosis progression. Interestingly, alcohol use was strongly associated with THC use and independently associated with liver fibrosis, and may better predict fibrosis progression in HCV/HIV co-infected women